Outcomes of Dissection Angles as Predictor of Restenosis after Drug-Coated Balloon Treatment

J Atheroscler Thromb. 2021 Sep 1;28(9):954-962. doi: 10.5551/jat.59774. Epub 2020 Oct 23.

Abstract

Aim: The predictors of restenosis after endovascular therapy (EVT) with paclitaxel drug-coated balloons (DCBs) have not been clearly established. The present study aimed to investigate the association of post-procedural dissection, as evaluated using intravascular ultrasound (IVUS), with the risk of restenosis following femoropopliteal EVT with paclitaxel DCBs.

Methods: In the present single-center retrospective study, 60 de novo femoropopliteal lesions (44 patients) that underwent EVT with DCBs, without bail-out stenting, were enrolled. The primary outcome was 1-year primary patency. Risk factors for restenosis were evaluated using a Cox proportional hazards regression model and random survival forest analysis.

Results: The 1-year primary patency rate was 57.2% [95% confidence interval, 45%-72%]. IVUS-evaluated post-procedural dissection was significantly associated with the risk of restenosis (P=0.002), with the best cutoff point of 64º [range, 39º-83º]. The random survival forest analysis showed that the variable importance measure of IVUS-evaluated dissection was significantly lower than that of the reference vessel diameter (P<0.001), not different from that of the lesion length (P=0.41), and significantly higher than that of any other clinical feature (all P<0.05).

Conclusion: IVUS-evaluated post-procedural dissection was associated with 1-year restenosis following femoropopliteal EVT with DCB.

Keywords: Dissection; Drug-coated balloon; Intravascular ultrasound; Peripheral artery disease; Restenosis.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Constriction, Pathologic / diagnosis
  • Constriction, Pathologic / etiology
  • Endovascular Procedures* / adverse effects
  • Female
  • Humans
  • Male
  • Paclitaxel / administration & dosage
  • Paclitaxel / therapeutic use*
  • Peripheral Arterial Disease / diagnosis
  • Peripheral Arterial Disease / therapy*
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome
  • Tubulin Modulators / administration & dosage
  • Tubulin Modulators / therapeutic use*
  • Vascular Access Devices* / adverse effects

Substances

  • Tubulin Modulators
  • Paclitaxel